Key Insights into Trump’s Reclassification of Medical Marijuana

(SeaPRwire) –   On April 23, acting U.S. Attorney General Todd Blanche authorized an order to adjust the federal classification of medical cannabis. This directive, initiated by President Donald Trump, reclassifies the substance as a Schedule 3 drug. According to experts, this change will provide significant tax advantages to medical marijuana producers across the 40 states where its medical use is permitted and could accelerate research into its therapeutic effects.

However, this action does not constitute federal legalization, nor does it alter the legal standing of marijuana intended for recreational use. Here are the essential details.

What is a Schedule 3 drug?

Within the Drug Enforcement Administration (DEA) framework, substances are categorized based on their recognized medical utility and potential for addiction. Since 1970, marijuana has been designated as a Schedule 1 drug, placing it alongside substances like heroin and LSD. Schedule 1 drugs are defined as having no accepted medical application and a high risk of dependency, with possession carrying potential legal penalties.

Medical marijuana will now be moved to Schedule 3, a category for substances with a moderate-to-low risk of addiction, which also includes testosterone and ketamine.

The federal reclassification of medical marijuana has been a subject of prior discussion, given its widespread use as a legal medical treatment at the state level; President Biden also advocated for such a change in 2024. Alex Stevens, a criminology professor at the University of Sheffield who researches cannabis policy, notes that several substances currently in Schedule 1 may be misclassified. For instance, he points out that MDMA is a “promising, but perhaps not yet proven, treatment for depression,” suggesting that other substances currently in Schedule 1 may also warrant re-evaluation.

What does the Justice Department order mean?

The order allows state-licensed medical marijuana producers to access tax deductions that were previously unavailable under the Schedule 1 designation.

Furthermore, the rescheduling may facilitate scientific study of cannabis-derived substances in the U.S. David Nutt, a professor of neuropsychopharmacology at Imperial College London, notes that cannabis research has been severely constrained by its previous classification.

Stevens adds that the order could simplify access to medical marijuana for some patients. He suggests that, in theory, it should make it easier for those requiring cannabis-based medical products to obtain them. If this leads to insurance coverage, it would be a major benefit for patients who currently struggle with the high costs of medical cannabis in the private market.

The order does not impact the legal status of recreational marijuana.

What will happen going forward?

This reclassification follows an April 18 executive order from President Trump aimed at expediting the review of psychedelics for medical treatment. Nutt suggests these recent developments indicate that many substances that were previously difficult to study—beyond just cannabis—may soon be easier to research.

Stevens anticipates that future policy shifts will be shaped by competing interests. He explains that the future of the cannabis market will be driven by the dynamic between three key groups: activists seeking broad access, medical regulators aiming to maintain oversight, and businesses focused on maximizing profitability.